Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals

International Journal of Antimicrobial Agents

Volumn 28, Issue 5, 2006, Pages 433-438

  Ludwig, Endre ^a   Konkoly Thege, Marianne ^a   Kuti, Joseph L ^b   Nicolau, David P ^b  

^a Szent Laszlo Hospital   (Hungary)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Antibiotics; Monte Carlo simulation; Pharmacodynamics; Pseudomonas aeruginosa; Resistance

Indexed keywords

BETA LACTAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; PIPERACILLIN; TAZOBACTAM;

ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CALCULATION; CONTROLLED STUDY; DRUG TARGETING; HOSPITAL; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CEPHALOSPORINS; CIPROFLOXACIN; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; HUNGARY; IMIPENEM; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 33750310169     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.07.014     Document Type: Article

References (28)

1. Gales A.C., Jones R.N., Turnidge J., Rennie R., and Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 32 Suppl. 2 (2001) S146-S155
2. Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., and Quinn J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289 (2003) 885-888
3. Unal S., and Garcia-Rodriguez J.A. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 53 (2005) 265-271
4. Gillespie E.L., Kuti J.L., and Nicolau D.P. Pharmacodynamics of antimicrobials: treatment optimisation. Expert Opin Drug Metab Toxicol 1 (2005) 351-361
5. Tam V.H., Louie A., Lomaestro B.M., and Drusano G.L. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 23 (2003) 291-295
6. Capitano B., Nicolau D.P., Potoski B.A., et al. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy 24 (2004) 803-807
7. Kuti J.L., Moss K.M., Nicolau D.P., and Knauft R.F. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 24 (2004) 1641-1645
8. Jumbe N., Louie A., Leary R., et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 112 (2003) 275-285
9. Tam V.H., Schilling A.N., Neshat S., Poole K., Melnick D.A., and Coyle E.A. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 49 (2005) 4920-4927
10. Turnidge J.D. The pharmacodynamics of β-lactams. Clin Infect Dis 27 (1998) 10-22
11. Wright D.H., Brown G.H., Peterson M.L., and Rotschafer J.C. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46 (2000) 669-683
12. Ambrose P.G., and Grasela D.M. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 38 (2000) 151-157
13. Bradley J.S., Dudley M.N., and Drusano G.L. Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 22 (2003) 982-992
14. Kuti J.L., Ong C., Lo M., Melnick D., Soto N., and Nicolau D.P. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents 28 (2006) 62-68
15. Kuti J.L., Nightingale C.H., and Nicolau D.P. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob Agents Chemother 48 (2004) 2464-2470
16. Kiffer C.R.V., Mendes C., Kuti J.L., and Nicolau D.P. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. Diagn Microbiol Infect Dis 49 (2004) 109-116
17. Masterton R.G., Kuti J.L., Turner P.J., and Nicolau D.P. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother 55 (2005) 71-77
18. Maglio D., Kuti J.L., and Nicolau D.P. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program. Clin Ther 27 (2005) 1032-1042
19. Sun H.K., Kuti J.L., and Nicolau D.P. Pharmacodynamics of antimicrobials for the empiric treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med 33 (2005) 2222-2227
20. Dandekar P.K., Maglio D., Sutherland C.A., Nightingale C.H., and Nicolau D.P. Pharmacokinetics of meropenem 0.5 and 2 g every 8 h as a 3-h infusion. Pharmacotherapy 23 (2003) 988-991
21. Lomaestro B.M., and Drusano G.L. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 49 (2005) 461-463
22. Jaruratanasirikul S., Sriwiriyajan S., and Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-h infusion or bolus injection. Antimicrob Agents Chemother 49 (2005) 1337-1339
23. Lodise T.P., Lomaestro B.M., and Drusano G.L. Evaluation of the clinical and economic implications of an extended infusion dosing strategy of piperacillin/tazobactam for Pseudomonas aeruginosa infections. Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (2004), American Society of Microbiology, Washington, DC p. 446 [abstract O-1617]
24. Lee L.S., Kinzig-Schippers M., Nafziger A.N., et al. Pharmacokinetics and pharmacodynamics of imipenem/cilastatin and meropenem using 30-minute and 3-h infusion in healthy volunteers. Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (2005), American Society of Microbiology, Washington, DC p. 11 [abstract A-223]
25. Montgomery M.J., Beringer P.M., Aminimanizani A., et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 45 (2001) 3468-3473
26. Gillespie E.L., Kuti J.L., and Nicolau D.P. When 'S' doesn't mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infections. Conn Med 69 (2005) 203-210
27. Kuti J.L., Horowitz S., Nightingale C.H., and Nicolau D.P. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. Pharmacotherapy 25 (2005) 935-941
28. Mouton J.W., Punt N., and Vinks A.A. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 27 (2005) 762-772